Kornimate/medical-research-clean huggingface dataset:
effect of breathing and muscle relaxation technique in individual with essential hypertension

Conditions: Essential Hypertension

Summary: primary hypertension, also called essential hypertension, is a rise in blood pressure (bp) with no identifiable cause. the most prevalent form of hypertension is essential hypertension, which involves 95% of patients with hypertension.progressive muscle relaxation (pmr) is learning to relax some groups of muscles while paying attention to the feelings connected with both the tense and relaxed states.it is generally established that regular slow (deep) breathing exercises enhance respiratory and cardiovascular function by enhancing parasympathetic tone and reducing sympathetic activity, thus reducing bp, heart rate, respiratory rate, and stress levels in hypertensive patients. this study aimed to investigate the combined effect of slow breathing and pmr technique on bp, heart rate, respiratory rate, and anxiety in patients diagnosed with essential hypertension.

from the previously published literature, it is obvious that both slow breathing and pmr and slow breathing is effective in patients with essential hypertension. however, no studies are available on the combined effect of these two techniques. so, the study aims to investigate the combined effect of slow breathing and pmr technique on bp, heart rate, respiratory rate, and anxiety in patients diagnosed with essential hypertension. sixty-four participants diagnosed with essential hypertension were randomly allocated into four groups (slow breathing (sb), pmr, sb+pmr, control) with 16 subjects in each. baseline bp, hr, rr and perceived stress scale were taken. all three-intervention groups underwent 30 minutes of training three days before the day of the intervention. the intervention consisted of 30 minutes, pre, mid and post-intervention bp, hr, rr and perceived stress (ps) were measured. the control group rested for 30 minutes. pre, mid and post-rest measurements of bp, hr, rr and ps were taken.

Eligibility criteria:
inclusion criteria: * participants with essential hypertension, a diastolic bp between 90 to 109mm of hg, a systolic bp of more than 140mm of hg, * aged between 30 to 60 years, and * self co-operation. exclusion criteria: * participants with secondary hypertension, any physical abnormalities that may disturb the exercise intervention, * participant who cannot perform any relaxation or breathing exercises, and * non-cooperation of participants.
3d animation and models to aid management of fetal cdh

Conditions: Congenital Diaphragmatic Hernia

Summary: we wish to use the images a mother would have done as part of her normal medical care and make both 3d animations and 3d models of the baby and it's cdh. this will both help the parents see what the problem is and also allow the surgeons, who will operate on the baby once it has been born, to see the size of the hole and what organs are in the wrong place.


Eligibility criteria:
inclusion criteria: * target population: pregnancy women attending jessop wing fetal medicine unit. * accessible population: pregnant women attending jessop wing fetal medicine unit. whose fetus had a cdh and are referred to mri. * study population: pregnant women attending jessop wing fetal medicine unit. whose fetus had a cdh and are referred to mri and agree to take part in the study. exclusion criteria: * not able to give informed consent due to any reason including poor understanding of english * under 18 years of age. * unable to complete the fetal mri process due to either metal implants or claustrophobia.
eus-guided ethanol ablation of an insulinoma

Conditions: Insulinoma

Summary: the present study aims to evaluate the feasibility, safety and efficacy of eus-guided ethanol ablation of an insulinoma.

as the major insulinomas are functioning islet cell tumors, surgical resection is currently first-line therapy for or treatment of insulinomas. however, the surgical resection of pancreatic neoplasm is conditional for specific patients and may be associated with substantial life-threatening complications. several studies declared that endoscopic ultrasound (eus)-guided lavage may offer an alternative to surgical resection of insulinomas. nevertheless, their sample sizes were small and conclusions were built based on short-term outcomes. in addition, the amount of ethanol administrated for different types of insulinomas were inconsistent among those studies. the present study aims to evaluate the safety, feasibility and efficacy of eus-guided ethanol ablation therapy of insulinomas. we will use cytopathology and immunohistochemistry in combination with eus-fna for diagnosis of insulinoma. after eus-guided ethanol ablation therapy, the safety and efficacy will be assessed at the baseline and different time points during follow-up by physicians blinded to the treatment or control status.

Eligibility criteria:
inclusion criteria: 1. adults: at least 18 years. 2. patients with insulinomas which are evaluated by histopathology . 3. patients who have signed a written consent form. exclusion criteria: 1. patients whose condition is not suitable for the endoscopic procedure. 2. patients who have blood coagulation dysfunction. 3. patients who have mental disorders. 4. patients who have mild or severe cardiorespiratory insufficiency. 5. patients who have hypertension and could not be controlled to safe level. 6. pregnant and lactating women. 7. patients whose conditions are not suitable for the present study.

Keywords: endoscopic ultrasound-guided fine needle aspiration insulinoma ethanol ablation techniques
study of insulin pump discontinuation in adults with diabetes

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine the rate of insulin pump discontinuation 18 months after initiation in patients with diabetes, and to determine factors associated with this discontinuation.

insulin pump discontinuation has been mostly studied in children and young adults living with diabetes, and rarely with a time-to-event analysis. we aim to evaluate the rate of insulin pump discontinuation after 18 months from initiation and factors associated with it in adults with diabetes. knowing these factors would allow better support for patients in difficulty.

Eligibility criteria:
inclusion criteria: all patients (adults and adolescents) with diabetes and an insulin pump initiation from 1 january 2015 to 30 june 2018 in the diabetes department of the centre hospitalier sud francilien. exclusion criteria: * pregnant women (or women planning pregnancy in the short term) with an insulin pump initiation from 1 january 2015 to 30 june 2018 * patients hospitalized for an insulin pump replacement or change between 1 january 2015 and 30 june 2018. * patients with a history of insulin pump initiation within a period of less than 6 months before a new pump start between 1 january 2015 and 30 june 2018.

Keywords: diabetes mellitus, type 1 diabetes mellitus, type 2 insulin infusion systems patient education
early screening and treatment of heart complication in sickle cell disease

Conditions: Sickle Cell Disease

Summary: this study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

the goal of the study is to detect iron-related heart problems in subjects with sickle cell disease (scd) through regular cardiac imaging (electrocardiogram, echocardiogram, cardiac mri) and lab testing every 3 months during the 12 months period. the treatment will be with iron chelation and guideline-directed heart medications.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosis of sickle cell disease (any genotype) * serum ferritin levels ≥ 400 ng/ml (up to 80 patients), or less than 400 ng/ml in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients) * willingness to undergo regular imaging (echocardiograms, ecg, cardiac mri) * ecog performance status of 0-1 * able to read, understand and provide written informed consent * deemed appropriate for participation by the treating physician exclusion criteria: * unable to schedule and required follow-up visits * medical comorbidities including: * known heart failure * unstable angina * uncontrolled dysrhythmias * acute pulmonary embolism * active infection or severe comorbid conditions that in the view of the investigator would limit participation * history of hypersensitivity or contraindication to chelation therapy * severe renal or hepatic impairment * pregnancy of breastfeeding

Keywords: iron overload cardiomyopathies arrhythmias
a study on the effect of kidney disease on a diabetes medication (0431-008)

Conditions: Renal Insufficiency; Hemodialysis

Summary: a study to evaluate the effect of kidney disease, from mild to severe disease, on a diabetes medication


Eligibility criteria:
inclusion criteria : * male and non-pregnant females with a clinical diagnosis of renal insufficiency with mild, moderate, severe or end stage renal disease on hemodialysis * a body mass index of less than 40 kg per meter squared (body weight in kg divided by height in meters squared) * smokes less than 10 cigarettes/day exclusion criteria : * patients with uncontrolled diabetes or uncontrolled congestive heart failure * patient has abnormal prestudy laboratory measurements including serum potassium or white blood counts * patient has systolic blood pressure below 100 mm hg or above 180 mm hg * patient has diastolic blood pressure less than 50 mm hg systolic or above 100 mmhg

Keywords: mild, moderate, severe renal insufficiency end stage renal disease
resistance training in patients with chronic obstructive lung disease (copd): whole body vibration versus conventional resistance training

Conditions: COPD

Summary: pulmonary rehabilitation has been emerged as a recommended standard of care for patients with chronic lung disease based on a growing body of scientific evidence. a set of evidence-based guidelines were published in american college of chest physicians (accp) and the american association of cardiovascular and pulmonary rehabilitation (aacvpr). since then, the published literature in pulmonary rehabilitation has increased substantially, and other societies have published important statements about pulmonary rehabilitation (eg, the american thoracic society and the european respiratory society). in patients with copd, there is a strong scientific basis for implementing conventional resistance training (crt) in addition to endurance training. endurance training, such as walking, is a key component of pulmonary rehabilitation and improves in exercise tolerance and muscular endurance. however, this type of training may not reverse muscle weakness or atrophy. for that reason, strength training seems to be the optimum training modality to increase muscle mass and strength. recently, whole-body-vibration (wbv) training has been promoted as an alternative for resistance training on multigym equipment. in wbv training, the subject stands on a platform that generates vertical sinusoidal vibration, during which static and dynamic exercises can be performed. the present study is conducted to provide an answer on the following question: will a resistance training program, such as the whole body vibration, be even effective than a conventional resistance training program in patients with copd.


Eligibility criteria:
inclusion criteria: * patients with copd candidate for pulmonary rehabilitation * men and female between 40 and 80 years of age * written informed consent to participate exclusion criteria: * severe cardiac, neurological and orthopedic co-morbidity interfering with exercise training. * pacemaker * hip, knee of shoulder prosthesis or recently introduced spirals, metal pens, bolts or plates * uncontrolled diabetes, epilepsy or migraine * osteoporotic or metastatic fractures, acute hernia, discopathy, spondylitis

Keywords: copd whole body vibration training conventional resistance training
effects of parenteral protein concentrations in critically ill patients

Conditions: Hand Muscle Strain

Summary: sixty patients who need parenteral nutrition for more than 48h will be assigned into two groups .group a (n=30) patient will receive 1g/kg/day protein and group b n=30) patient will receive 2g /kg/day. in both groups caloric requirement will be fixed at 25- 30 kcal /kg/d.

in this study after obtaining approval from our hospital ethics committee, a written informed consent will be obtained from patient's next of kin. sixty patients who need pn for more than 48h will be assigned into two groups .group a (n=30) patient will receive 1g/kg/day protein and group b n=30) patient will receive 2g /kg/day. in both groups caloric requirement will be fixed at 25- 30 kcal /kg/d. inclusion criteria: age: from 18 to 60 years sex : male or female predicted to be in icu ≥ 48 hs predicted to have pn for\> 48 hs. exclusion criteria: pregnant female hepatic patients renal patients age \<18 years technique of the study : 60 abdominal surgery/trauma icu patients who have a contraindication or intolerance to enteral nutrition(en),will be fed parenterally within 24-48 h from admission and divided according to the protein delivery into two groups. group a , those patients will receive parenteral proteins in a dose of 1 g/kg/day. group b, those patients will receive parenteral proteins in a dose of 2g/kg /day the nutrition will be delivered through a central line and using separate bottles technique ,because of the lack of a compounding unit and commercial bags in our hospital, after exclusion of the protein calories (will be given as 10%aa )the rest of energy requirement will be divided between carbohydrates (glucose25%)and lipids(smof20%) in a ratio of 60:40 serum electrolytes, blood glucose, lipid profile and serum creatinine will be monitored and corrected regularly in every patient the two groups will be compared as regarding the following : hand grip strength time of staying on icu time of staying in hospital ultrasound biceps muscle thickness nitrogen balances

Eligibility criteria:
inclusion criteria: * age: from 18 to 70 years sex : male or female predicted to be in icu ≥ 48 hs predicted to have pn for\> 48 hs. exclusion criteria: - hepatic patients renal patients age \<18 years

Keywords: protein parenteral critical ill patient icu
golimumab in ulcerative colitis (uc) patients with loss of response (lor) followed by dose optimization

Conditions: Ulcerative Colitis

Summary: it is planned to enroll 80 uc patients who will require optimization of golimumab after secondary lor. the review of the study protocol and its approval by an independent ethics committee of the university of saint etienne are pending. all patients enrolled will give their written informed consent before being included. this study will be conducted in accordance with the ethical principles that have their origins in the declaration of helsinki, in compliance with the approved protocol, good clinical practice and applicable regulatory requirements. patients will visit the investigator from screening visit to visit 6 at w-1, w0, w2, w4, w8, and at the end of the follow-up at wk 24. during their participation, patients will record clinical parameters required to calculate the partial mayo score reported over 3 days prior to the visit and endoscopy at w0, w2 (optional) , w4, w8 (optional) and at the end of the follow-up to calculate total mayo score.


Eligibility criteria:
inclusion criteria: * affiliate or beneficiary of social security * age\>18 years * pregnant women or man * presenting primary response under golimumab induction and in loss of response during maintenance therapy * patient with an ulcerative colitis * treated with golimumab * signature of consent exclusion criteria: * trying to become pregnant * mental or emotional disorders * patients with crohn's disease or indeterminate colitis * cancer(\<5) * patients not in agreement with this study protocol * patients with crohn's disease or indeterminate colitis * patients non primary responder to golimumab

Keywords: golimumab clinical response mayo score rectosigmoidoscopy ulcerative colitis
safety of a influenza vaccine produced either in mammalian cell culture or in embryonated hen eggs in adults and elderly with and without underlying medical conditions, and immunogenicity in a subset of subjects with underlying medical conditions

Conditions: Seasonal Influenza; Vaccine

Summary: evaluation of the safety of trivalent subunit influenza vaccine produced either in mammalian cell culture or in embryonated hen eggs in subjects 18 years of age and above with and without underlying medical conditions and evaluation of the immunogenicity in a subset of subjects with underlying medical conditions, compared to an egg-based vaccine in a post marketing setting.


Eligibility criteria:
inclusion criteria: 1. subjects 18 years of age and above, mentally competent, willing and able to give informed consent prior to study entry; 2. able to comply with all study procedures and requirements. exclusion criteria: 1. history of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any vaccine component; 2. fatal prognosis of an underlying medical condition (\<12 months life expectancy); 3. history of guillain-barre syndrome; 4. bleeding diathesis or receiving anticoagulants of the coumarin type; 5. hospitalization or residence in a nursing care facility; 6. planned to receive seasonal influenza vaccine outside of this study; 7. receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study; 8. fever (defined as axillary temperature ≥38.0°c) or any acute illness within 3 days prior to study vaccination; 9. receipt of another investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study, whichever is longer, and unwilling to refuse participation in another clinical study through the end safety follow up period of the study; 10. any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives; 11. females who were pregnant or nursing (breastfeeding) mothers, or females of childbearing potential who were sexually active and had not used or did not plan to use acceptable birth control measures during the first 3 weeks after vaccination. oral, injected or implanted hormonal contraceptive, diaphragm or condom with spermicidal agent or intrauterine device were considered acceptable forms of birth control.

Keywords: influenza vaccine
hearing aid quality and reliability study

Conditions: Hearing Loss

Summary: quality and reliability study of hearing aid. adults with mild to severe hearing loss will wear hearing aids daily for approximately 3 months.


Eligibility criteria:
inclusion criteria: * adults with mild to moderate severe sensorineural hearing loss * adults who were able to incorporate some type of physical activity into their day (i.e walking, excercise, gardening, etc.) exclusion criteria: * unable or unwilling to wear study devices during a home trial * unable or unwilling to come to lab for study visits
comparative study of lobaplatin and paclitaxel in advanced gastric cancer patients with d2 surgery combined with hyperthermic intraperitoneal chemotherapy

Conditions: Gastric Cancer; Chemotherapy Effect; Surgery; Metastasis; Survival

Summary: this study is a prospective, randomized, comparative clinical trial conducted by wuhan union hospital and aim to compare the therapeutic effects of lobaplatin and paclitaxel in advanced gastric cancer patients with d2 surgery combined with hyperthermic intraperitoneal chemotherapy

hyperthermic intraperitoneal chemotherapy (hipec) is traditionally used to treat peritoneal cancer combined with cytoreductive surgery (crs). further, there have been lots of randomized clinical trials assessing the efficacy of surgery + hipec for the treatment of locally advanced gastric cancer conducted. nonetheless, to date, the kinds, doses, combinations of hipec drugs are not clearly been evaluate a criterion. thus, this study aim to compare the efficacy of lobaplatin and paclitaxel in advanced gastric cancer patients with d2 surgery combined with hipec. we plan to recruit 231 patients and divide into 3 groups, 2 drug groups and 1 control groups, radomly. all patients with advanced gastric cancer receive d2 surgery + hipec + sox/xelox chemotherapy regimen. the mainly experimental variable is hipec drugs and three groups employ lobaplatin, paclitaxel and none respectively. the endpoints of study include peritoneal metastasis, overall survival, immune status and perioperative safety assessment.

Eligibility criteria:
inclusion criteria: 1. no chemoradiotherapy or other anti-tumor therapy before clinical trial performed; 2. aged 18-75 years; 3. male or non-pregnant or lactating women; 4. pathological diagnosis of gastric adenocarcinoma; 5. clinical diagnosis of t3 stage or above without distant metastasis and can be given d2 radical resection (ajcc version 8, 2018); 6. normal function of major organs; 7. routine blood examinations meeting the following criteria: a. hb ≥ 90 g/l; b. anc ≥ 1.5 x 10 9 /l; c. plt ≥ 125 × 10 9 /l; 8. chemistry indexs meeting the following criteria: a. tbil \ 30 g/l c. serum cr ≤ 1.25 uln or endogenous creatinine clearance \> 50 ml/min (cockcroft-gault formula); 9. ecog score 0-1; exclusion criteria: 1. a history of other malignant tumors within 5 years; 2. distant metastasis found during surgery; 3. allergic to paclitaxel, lobaplatin and other related chemotherapeutic drugs; 4. suffering from epilepsy or other mental illness, unable to control behavior; 5. inability to tolerate surgery due to severe cardiac, pulmonary and vascular disease; 6. pregnant or lactating women. 7. receiving anti-cancer drug therapy from other clinical trials.

Keywords: advanced gastric cancer hyperthermic intraperitoneal chemotherapy lobaplatin paclitaxel prognosis
segmentectomy for solid-dominant lung cancer

Conditions: Segmentectomy; Lung Adenocarcinoma

Summary: this is a clinical trial from eastern cooperative thoracic oncology project (ectop), numbered as ectop-1025. the goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. the main questions it aims to answer are: * the 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of 2-3cm; * the post-operative lung function tests after receiving segmentectomy. participants will receive segmentectomy as the surgical procedure.


Eligibility criteria:
inclusion criteria: * patients who sign the informed consent form and are willing to complete the study according to the plan; * aged from 18 to 80 years old; * ecog equals 0 or 1; * not receiving lung cancer surgery before; * confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively; * ground glass-dominant lung nodules * consolidation-to-tumor ratio (ctr) ranges from 0.5 to 1, and tumor size ranges from 2 to 3cm; * cn0 without distant metastasis; * tumors could be completely resected assed by surgeons; * not receiving chemotherapy or radiotherapy before. exclusion criteria: * ctr is not 0.5-1, or size is not 2-3cm; * tumors could not be completely resected assed by surgeons; * not lung adenocarcinoma diagnosed cytologically or pathologically; * receiving lung cancer surgery before; * receiving radiotherapy or chemotherapy.